HLB to Join US 'Cancer Moonshot' Project... "Strengthening Big Pharma Networking"

Public-Private Council 'CancerX' Joins as Member

HLB announced on the 26th that it has joined the public-private consortium 'Cancer X' and will officially participate in the United States' cancer conquest project, 'Cancer Moonshot.'

HLB is registered at the bottom right of the CancerX member company list.
[Image provided by HLB]

Cancer X is a public-private partnership established primarily by the Moffitt Cancer Center, a U.S. cancer research institute, and the Digital Medicine Society (DiME). It is effectively leading the Biden administration's 'Cancer Moonshot' policy, which aims to reduce cancer mortality by more than 50% over the next 25 years.

HLB, currently undergoing FDA's new drug approval review for its first-line treatment for liver cancer, plans to strengthen its network with related organizations and companies in the U.S. through its participation in Cancer X.

Previously, last month, HLB Panagen joined as a member of Cancer X. As a result, two companies within the HLB Group will participate in the U.S. government-led cancer conquest project in the fields of diagnosis and treatment.

In addition to the liver cancer treatment drug, Lenvatinib, HLB is developing DNA therapeutic vaccines for glioblastoma (GBM) and Merkel cell carcinoma, as well as next-generation chimeric antigen receptor (CAR)-T therapies for various solid tumors through its subsidiaries Immunomic and Verismo.

Baek Yoon-ki, CEO of HLB, said, "HLB, which is leading in the diagnosis and treatment of cancer patients, will actively contribute to improving the quality of life for cancer patients worldwide through this participation in Cancer X. Since many global big pharma companies are also participating in Cancer X, we will expand the horizon of anticancer drug development through close cooperation in the future."

Meanwhile, global big pharma companies such as Johnson & Johnson, Takeda, and AstraZeneca are participating in Cancer X alongside HLB and HLB Panagen.